Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain's 'Optimism' and 'Pessimism' signals mapped in Parkinson's study

NCT ID NCT07402928

Knowledge-focused Sponsor: Danish Research Centre for Magnetic Resonance Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how the brain processes optimistic and pessimistic signals related to dopamine, a chemical that helps control movement and mood. Researchers will compare 70 people with Parkinson's disease and 70 healthy volunteers using brain scans while they play a reward-based game. The goal is to understand why Parkinson's symptoms occur and how medication might affect these brain signals.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 140 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with PD and healthy volunteers, who are age- and sex-matched to the PD group.

Ages

35 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

PD PATIENTS: Inclusion Criteria: * At least 35 years of age. * Clinically established or probable PD according to the Movement Disorder Society Clinical Diagnostic Criteria for Parkinson's Disease * Akinetic-rigid type PD * Stable antiparkinsonian medicine for 4 weeks without major side effects such as dyskinesia or on-off periods. * Signed informed consent. Exclusion Criteria: * Female participants of childbearing age must not be pregnant, and they must use contraception. * Breastfeeding. * History of other neurologic or psychiatric disease other than depression. * Claustrophobia, pacemakers, implanted electronic devices, metal in the body, or other contraindications for MR scans. * Patients receiving advanced PD treatment such as duodopa pump or apomorphine pen * Regular intake of antipsychotics and GABAergic medications (such as pregabalin and gabapentine). * Severe depression (MDI score \> 29). * Refuse to be informed about new health-related findings that might appear through participation. HEALTHY CONTROLS: Inclusion criteria: * At least 35 years of age. * Signed informed consent. Exclusion criteria: * Female participants of childbearing age must not be pregnant, and they must use contraception. * Breastfeeding. * History of neurologic or psychiatric disease other than depression. * Claustrophobia, pacemakers, implanted electronic devices, metal in the body, or other contraindications for MR scans. * Regular intake of antipsychotics and GABAergic medications (such as pregabalin and gabapentine). * Severe depression (MDI score \> 29). * Refuse to be informed about new health-related information and accidental health-related findings that might appear through participation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Healthy Medication administration Parkinson

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Danish Research Centre for Magnetic Resonance (DRCMR), Hvidovre Hospital

    RECRUITING

    Hvidovre, 2650, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.